7 completed, 2 terminated, 1 withdrawn. 6 Phase 1, 3 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 6 |
| Phase 2 | 3 | Completed 1, Terminated 1, Withdrawn 1 |
| Phase 3 | 2 | Terminated 2 |
Follow eleclazine: new trials by email Literature Review of eleclazine trials Research Report on eleclazine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Effect of Eleclazine on QT, Safety, and Tolerability in Participants With Long QT2 Syndrome Eleclazine, Placebo - LQT2 Syndrome | Phase 1 | Completed | Gilead Sciences | 13 | 2015-07-20 | 2020-12-30 |
| Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function Eleclazine - Long QT Syndrome | Phase 1 | Completed | Gilead Sciences | 55 | 2015-05-01 | 2015-12-22 |
| GS-6615 in Adults With Chronic Stable Angina and Coronary Artery Disease GS-6615, Placebo - Ischemic Heart Disease | Phase 2 | Withdrawn | Gilead Sciences | 2015-05-01 | 2015-06-08 | |
| Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function Eleclazine - Long QT Syndrome | Phase 1 | Completed | Gilead Sciences | 49 | 2015-03-19 | 2019-07-29 |
| Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy Eleclazine, Placebo - Hypertrophic Cardiomyopathy | Phase 2 / Phase 3 | Terminated | Gilead Sciences | 172 | 2015-02-05 | 2018-09-24 |
| Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults GS-6615, Placebo to match GS-6615, Placebo to match dofetilide - Long QT Syndrome | Phase 1 | Completed | Gilead Sciences | 60 | 2015-02-01 | 2015-05-20 |
| Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3 Eleclazine, Eleclazine placebo - Long QT Syndrome Type 3 | Phase 3 | Terminated | Gilead Sciences | 41 | 2014-12-17 | 2018-01-12 |
| Evaluating Ventricular Arrhythmia in Subjects With Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy-Defibrillator Eleclazine, Placebo to match eleclazine - Ventricular Arrhythmia | Phase 2 | Completed | Gilead Sciences | 313 | 2014-09-01 | 2019-04-09 |
| Study of the Effect of GS-6615 in Subjects With LQT-3 GS-6615 - Long QT Syndrome | Phase 1 | Completed | Gilead Sciences | 24 | 2013-05-01 | 2014-11-17 |
| A Phase 1 Study to Assess the Safety,Tolerability, and Pharmacokinetics of GS-6615 in Healthy Subjects GS-6615, Placebo - Ischemic Heart Disease | Phase 1 | Completed | Gilead Sciences | 36 | 2013-05-01 | 2013-11-13 |
Long QT Syndrome (5) · Angina Pectoris (2) · Death, Sudden, Cardiac (2) · Myocardial Ischemia (2) · Angina, Stable (1) · Cardiomyopathies (1) · Cardiomyopathy, Hypertrophic (1) · Cardiomyopathy, Hypertrophic, Familial (1) · Coronary Artery Disease (1) · Coronary Disease (1) · Dyspnea (1) · Heart Diseases (1) · Heart Failure (1) · Hypertrophy (1) · Long QT syndrome type 3 (1)
Gilead Sciences (10)
United States (9) · Germany (4) · Israel (3) · Netherlands (3) · Canada (2) · France (2) · Italy (2) · Romania (2) · United Kingdom (2) · Australia (1) · Czechia (1) · Denmark (1) · Hungary (1) · Moldova (1) · New Zealand (1)
Elizabeth Layug, MD (2) · Brian McNabb, MD (1) · Kimberly B Patel, MD (1) · Patrick Yue, MD (1)
2014 (4)